First human trial of COVID-19 vaccine Succeeds to Induces Rapid Immune Response

Study of 108 adults finds vaccine produced neutralising antibodies and T-cell response against SARS-CoV-2

The first COVID-19 vaccine phase 1 clinical trial established safety and was able to generate an immune response against SARS-CoV-2 in humans. The results of the trial was published recently in The Lancet.

“These results represent an important milestone. The trial demonstrates that a single dose of the new adenovirus type 5 vectored COVID-19 (Ad5-nCoV) vaccine produces virus-specific antibodies and T cells in 14 days, making it a potential candidate for further investigation,” says Professor Wei Chen from the Beijing Institute of Biotechnology in Beijing, China, who is responsible for the study. “However, these results should be interpreted cautiously. The challenges in the development of a COVD-19 vaccine are unprecedented, and the ability to trigger these immune responses does not necessarily indicate that the vaccine will protect humans from COVID-19. This result shows a promising vision for the development of COVID-19 vaccines, but we are still a long way from this vaccine being available to all.”


According to new research published in The Lancet The open-label trial in 108 healthy adults demonstrates promising results after 28 days—the final results will be evaluated in six months [1]. Further trials are needed to tell whether the immune response it elicits effectively protects against SARS-CoV-2 infection.

The study was funded by National Key R&D Program of China, National Science and Technology Major Project, and CanSino Biologic. It was conducted by researchers from Beijing Institute of Biotechnology, Beijing, China; and a number of other key sites.

The creation of an effective vaccine is seen as the long-term solution to controlling the COVID-19 pandemic. Currently, there are more than 100 candidate COVID-19 vaccines in development worldwide.

Support us in our endeavor to bring you Advertisement free content.
Choose your options to donate or subscribe.


Related Articles

Leave a Reply

Back to top button